Imsidolimab

Generalized pustular psoriasis

Manufacturer: Vanda Pharmaceuticals
Regulatory submission: BLA submitted December 2025
Launch: Anticipated in the first half of 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment

Current treatment options and standard of care

18 evidence topics · 9 sources

IL-36 receptor inhibitors1 evidence topic · 1 source
TNF inhibitors2 evidence topics · 1 source
IL-17 inhibitors1 evidence topic · 1 source
IL-23 inhibitors1 evidence topic · 1 source
Conventional systemic therapies2 evidence topics · 3 sources
Topical therapies2 evidence topics · 2 sources
Phototherapy1 evidence topic · 1 source
Granulocyte and monocyte adsorption apheresis1 evidence topic · 1 source
Supportive care1 evidence topic · 1 source
Limitations of current therapies6 evidence topics · 4 sources